CLINICAL PHARMACOLOGY Mechanism of Action:
The mechanism of action of lurasidone, as with other drugs having efficacy in
schizophrenia, is unknown. It has been suggested that the efficacy of lurasidone
in schizophrenia is mediated through a combination of central dopamine Type 2
(D2) and serotonin Type 2 (5HT2A) receptor antagonism.
INDICATIONS AND USAGE
LATUDA is indicated for the treatment of patients with schizophrenia.
The efficacy of LATUDA in schizophrenia was established in four 6-week
controlled studies of adult patients with schizophrenia.
The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks,
has not been established in controlled studies. Therefore, the physician who
elects to use LATUDA for extended periods should periodically re-evaluate the
long-term usefulness of the drug for the individual patient.
DOSAGE AND ADMINISTRATION Schizophrenia:
The recommended starting dose of LATUDA is 40 mg once daily. Initial dose
titration is not required. LATUDA has been shown to be effective in a dose range
of 40 mg/day to 120 mg/day. In the 6-week controlled trials, there was no
suggestion of added benefit with the 120 mg/day dose, but there was a
dose-related increase in certain adverse reactions. Therefore, the maximum
recommended dose is 80 mg/day.
Administration Instructions: LATUDA should be taken with food
(at least 350 calories)
Dosage in Special Populations: Renal Impairment:
It is recommended that LATUDA dose should not exceed 40 mg/day in
patients with moderate and severe renal impairment (Clcr
10 mL/min to < 50
After administration of a single dose of 40 mg LATUDA to patients with
mild, moderate and severe renal impairment, mean Cmax increased by 40%,
92% and 54%, respectively and mean AUC increased by 53%, 91% and 2-
times, respectively compared to healthy matched subjects.
Dose adjustment is recommended in moderate and
severe hepatic impairment patients. The dose in these
patients should not exceed 40 mg/day. Dosing recommendation for patients taking LATUDA concomitantly
with potential CYP3A4 inhibitors: When coadministration of
LATUDA with a moderate CYP3A4 inhibitor such as diltiazem is considered,
the dose should not exceed 40 mg/day. LATUDA should not be used in
combination with a strong CYP3A4 inhibitor (e.g., ketoconazole).
Dosing recommendation for patients taking LATUDA concomitantly
with potential CYP3A4 inducers: LATUDA should not be used in
combination with a strong CYP3A4 inducer (e.g., rifampin).
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read